OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Phase 3
Completed
Conditions
First Posted Date
2003-10-21
Last Posted Date
2012-05-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
3600
Registration Number
NCT00071331
Locations
๐Ÿ‡ณ๐Ÿ‡ด

Hjertemed.avd. Akershus Universitetssykenhus, Nordbyhagen, Norway

๐Ÿ‡ณ๐Ÿ‡ด

Diakonhjemmets sykehus Oslo, Oslo, Norway

๐Ÿ‡บ๐Ÿ‡ธ

The Heart and Vascular Institute of Florida, St. Petersburg, Florida, United States

and more 352 locations

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Phase 3
Completed
Conditions
First Posted Date
2003-07-10
Last Posted Date
2012-05-10
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
375
Registration Number
NCT00064454
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Affiliates in Gastroeneterology, Florham Park, New Jersey, United States

๐Ÿ‡บ๐Ÿ‡ธ

Gastrointestial Associates, PA, Jackson, Mississippi, United States

and more 25 locations

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Phase 3
Completed
Conditions
First Posted Date
2003-07-10
Last Posted Date
2012-05-10
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
375
Registration Number
NCT00064441
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Akron Gastroenterology Associates, Inc., Akron, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Lovelace Scientific Resources Florida, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Miami Research Associates, Miami, Florida, United States

and more 20 locations

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

Phase 3
Completed
Conditions
First Posted Date
2002-10-01
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00046384
Locations
๐Ÿ‡ฆ๐Ÿ‡ท

Local Institution, Mendoza, Argentina

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

Phase 2
Completed
Conditions
First Posted Date
2002-08-14
Last Posted Date
2005-06-24
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
170
Registration Number
NCT00043758
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Midwest Cardiology Research Foundation, Columbus, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Guthrie Clinic, LTD, Sayre, Pennsylvania, United States

and more 37 locations

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Phase 2
Completed
Conditions
First Posted Date
2002-08-14
Last Posted Date
2005-06-24
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
40
Registration Number
NCT00043771
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Central Cardiology Medical Clinic, Bakersfield, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis University, St. Louis, Missouri, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California-San Diego, San Diego, California, United States

and more 6 locations

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Phase 3
Completed
Conditions
First Posted Date
2002-07-15
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00041678
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Milwaukee, Wisconsin, United States

Study of Aripiprazole in Patients With a History of Bipolar Disorder

Phase 3
Completed
Conditions
First Posted Date
2002-05-10
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00036348
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, San Antonio, Texas, United States

Broad Effectiveness: Study With Aripiprazole

Phase 3
Completed
Conditions
First Posted Date
2002-05-10
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
444
Registration Number
NCT00036361
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Wallingford, Connecticut, United States

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

Phase 3
Completed
Conditions
First Posted Date
2002-05-09
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00036101
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution, Bellevue, Washington, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath